BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen S, Wang Y, Wang C, Wu YN, Xing Y. SURVIV for survival analysis of mRNA isoform variation. Nat Commun 2016;7:11548. [PMID: 27279334 DOI: 10.1038/ncomms11548] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Wu P, Chen Y, Meng Q, Dawood H, Dawood H. A hierarchical integration deep flexible neural forest framework for cancer subtype classification by integrating multi-omics data. BMC Bioinformatics 2019;20:527. [PMID: 31660856 DOI: 10.1186/s12859-019-3116-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
2 Singh B, Eyras E. The role of alternative splicing in cancer. Transcription 2017;8:91-8. [PMID: 28005460 DOI: 10.1080/21541264.2016.1268245] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
3 Xu N, Ke ZB, Lin XD, Lin F, Chen SH, Wu YP, Chen YH, Wei Y, Zheng QS. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data. Aging (Albany NY) 2020;12:4996-5009. [PMID: 32217810 DOI: 10.18632/aging.102924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 West S, Kumar S, Batra SK, Ali H, Ghersi D. Uncovering and characterizing splice variants associated with survival in lung cancer patients. PLoS Comput Biol 2019;15:e1007469. [PMID: 31652257 DOI: 10.1371/journal.pcbi.1007469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Krstic M, Hassan HM, Kolendowski B, Hague MN, Anborgh PH, Postenka CO, Torchia J, Chambers AF, Tuck AB. Isoform-specific promotion of breast cancer tumorigenicity by TBX3 involves induction of angiogenesis. Lab Invest 2020;100:400-13. [PMID: 31570773 DOI: 10.1038/s41374-019-0326-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tan DJ, Mitra M, Chiu AM, Coller HA. Intron retention is a robust marker of intertumoral heterogeneity in pancreatic ductal adenocarcinoma. NPJ Genom Med 2020;5:55. [PMID: 33311498 DOI: 10.1038/s41525-020-00159-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Xu A, Wang X, Luo J, Zhou M, Yi R, Huang T, Lin J, Wu Z, Xie C, Ding S, Zeng Y, Song Y. Overexpressed P75CUX1 promotes EMT in glioma infiltration by activating β-catenin. Cell Death Dis 2021;12:157. [PMID: 33542188 DOI: 10.1038/s41419-021-03424-1] [Reference Citation Analysis]
8 Jin P, Tan Y, Zhang W, Li J, Wang K. Prognostic alternative mRNA splicing signatures and associated splicing factors in acute myeloid leukemia. Neoplasia 2020;22:447-57. [PMID: 32653835 DOI: 10.1016/j.neo.2020.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z, He J. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett 2017;393:40-51. [PMID: 28223168 DOI: 10.1016/j.canlet.2017.02.016] [Cited by in Crossref: 93] [Cited by in F6Publishing: 105] [Article Influence: 18.6] [Reference Citation Analysis]
10 Mao S, Li Y, Lu Z, Che Y, Sun S, Huang J, Lei Y, Wang X, Liu C, Zheng S, Zang R, Li N, Li J, Sun N, He J. Survival-associated alternative splicing signatures in esophageal carcinoma. Carcinogenesis 2019;40:121-30. [PMID: 30304323 DOI: 10.1093/carcin/bgy123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
11 Liu Y, Jia W, Li J, Zhu H, Yu J. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma. Front Oncol 2020;10:587343. [PMID: 33117720 DOI: 10.3389/fonc.2020.587343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Qiu Y, Lyu J, Dunlap M, Harvey SE, Cheng C. A combinatorially regulated RNA splicing signature predicts breast cancer EMT states and patient survival. RNA 2020;26:1257-67. [PMID: 32467311 DOI: 10.1261/rna.074187.119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Ke H, Zhao L, Zhang H, Feng X, Xu H, Hao J, Wang S, Yang Q, Zou L, Su X, Wang L, Wu C, Wang Y, Nie J, Jiao B. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc Natl Acad Sci U S A 2018;115:E3426-35. [PMID: 29581274 DOI: 10.1073/pnas.1714573115] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
14 Shao Y, Chong W, Liu X, Xu Y, Zhang H, Xu Q, Guo Z, Zhao Y, Zhang M, Ma Y, Gu F. Alternative splicing-derived intersectin1-L and intersectin1-S exert opposite function in glioma progression. Cell Death Dis 2019;10:431. [PMID: 31160551 DOI: 10.1038/s41419-019-1668-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Schmitz U, Shah JS, Dhungel BP, Monteuuis G, Luu PL, Petrova V, Metierre C, Nair SS, Bailey CG, Saunders VA, Turhan AG, White DL, Branford S, Clark SJ, Hughes TP, Wong JJ, Rasko JEJ. Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. Cancers (Basel) 2020;12:E3738. [PMID: 33322625 DOI: 10.3390/cancers12123738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Xi X, Li T, Huang Y, Sun J, Zhu Y, Yang Y, Lu ZJ. RNA Biomarkers: Frontier of Precision Medicine for Cancer. Noncoding RNA 2017;3:E9. [PMID: 29657281 DOI: 10.3390/ncrna3010009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
17 Sun T, Yang Q. Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. Oncol Lett 2020;20:420-30. [PMID: 32565967 DOI: 10.3892/ol.2020.11562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Du Y, Li S, Du R, Shi N, Arai S, Chen S, Wang A, Zhang Y, Fang Z, Zhang T, Ma W. Modularized Perturbation of Alternative Splicing Across Human Cancers. Front Genet 2019;10:246. [PMID: 31024612 DOI: 10.3389/fgene.2019.00246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Zhu J, Chen Z, Yong L. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol 2018;148:368-74. [PMID: 29191436 DOI: 10.1016/j.ygyno.2017.11.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
20 Namba S, Ueno T, Kojima S, Kobayashi K, Kawase K, Tanaka Y, Inoue S, Kishigami F, Kawashima S, Maeda N, Ogawa T, Hazama S, Togashi Y, Ando M, Shiraishi Y, Mano H, Kawazu M. Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer. Commun Biol 2021;4:1320. [PMID: 34811492 DOI: 10.1038/s42003-021-02833-4] [Reference Citation Analysis]
21 Gallego-Paez LM, Bordone MC, Leote AC, Saraiva-Agostinho N, Ascensão-Ferreira M, Barbosa-Morais NL. Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems. Hum Genet 2017;136:1015-42. [PMID: 28374191 DOI: 10.1007/s00439-017-1790-y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
22 Sun Y, Li C, Pang S, Yao Q, Chen L, Li Y, Zeng R. Kinase-substrate Edge Biomarkers Provide a More Accurate Prognostic Prediction in ER-negative Breast Cancer. Genomics Proteomics Bioinformatics 2020;18:525-38. [PMID: 33450402 DOI: 10.1016/j.gpb.2019.11.012] [Reference Citation Analysis]
23 Zhang B, Wu Q, Cheng S, Li W. Systematic Profiling of mRNA Splicing Reveals the Prognostic Predictor and Potential Therapeutic Target for Glioblastoma Multiforme. J Oncol 2021;2021:4664955. [PMID: 34326872 DOI: 10.1155/2021/4664955] [Reference Citation Analysis]
24 Simpson E, Chen S, Reiter JL, Liu Y. Differential Splicing of Skipped-exons Predicts Drug Response in Cancer Cell Lines. Genomics Proteomics Bioinformatics 2021:S1672-0229(21)00043-7. [PMID: 33662622 DOI: 10.1016/j.gpb.2019.08.003] [Reference Citation Analysis]
25 Liu Z, Ye J, Khan AA, Chen J, Zhou L, Zheng S, Xu X. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma. Med Sci Monit 2021;27:e930052. [PMID: 34407065 DOI: 10.12659/MSM.930052] [Reference Citation Analysis]
26 Chen K, Ye H, Lu XJ, Sun B, Liu Q. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. Trends Pharmacol Sci 2017;38:1041-51. [PMID: 29089139 DOI: 10.1016/j.tips.2017.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
27 Pani T, Rajput K, Kar A, Sharma H, Basak R, Medatwal N, Saha S, Dev G, Kumar S, Gupta S, Mukhopadhyay A, Malakar D, Maiti TK, Arimbasseri AG, Deo SVS, Sharma RD, Bajaj A, Dasgupta U. Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype. Cell Death Dis 2021;12:171. [PMID: 33568634 DOI: 10.1038/s41419-021-03436-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ouyang D, Yang P, Cai J, Sun S, Wang Z. Comprehensive analysis of prognostic alternative splicing signature in cervical cancer. Cancer Cell Int 2020;20:221. [PMID: 32528230 DOI: 10.1186/s12935-020-01299-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
29 Zhang D, Zou D, Deng Y, Yang L. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing. J Ovarian Res 2021;14:120. [PMID: 34526089 DOI: 10.1186/s13048-021-00866-1] [Reference Citation Analysis]
30 Darrigrand R, Pierson A, Rouillon M, Renko D, Boulpicante M, Bouyssié D, Mouton-Barbosa E, Marcoux J, Garcia C, Ghosh M, Alami M, Apcher S. Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens. Commun Biol 2021;4:269. [PMID: 33649389 DOI: 10.1038/s42003-021-01801-2] [Reference Citation Analysis]
31 Zhao S. Alternative splicing, RNA-seq and drug discovery. Drug Discov Today. 2019;24:1258-1267. [PMID: 30953866 DOI: 10.1016/j.drudis.2019.03.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
32 Wu HY, Wei Y, Liu LM, Chen ZB, Hu QP, Pan SL. Construction of a model to predict the prognosis of patients with cholangiocarcinoma using alternative splicing events. Oncol Lett 2019;18:4677-90. [PMID: 31611977 DOI: 10.3892/ol.2019.10838] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Guo Y, Zheng J, Shang X, Li Z. A Similarity Regression Fusion Model for Integrating Multi-Omics Data to Identify Cancer Subtypes. Genes (Basel) 2018;9:E314. [PMID: 29933539 DOI: 10.3390/genes9070314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
34 Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Proc Natl Acad Sci U S A 2020;117:5269-79. [PMID: 32086391 DOI: 10.1073/pnas.1915975117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
35 Zhang N, Zhang P, Chen Y, Lou S, Zeng H, Deng J. Clusterization in acute myeloid leukemia based on prognostic alternative splicing signature to reveal the clinical characteristics in the bone marrow microenvironment. Cell Biosci 2020;10:118. [PMID: 33062256 DOI: 10.1186/s13578-020-00481-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Zhu Y, Wang S, Xi X, Zhang M, Liu X, Tang W, Cai P, Xing S, Bao P, Jin Y, Zhao W, Chen Y, Zhao H, Jia X, Lu S, Lu Y, Chen L, Yin J, Lu ZJ. Integrative analysis of long extracellular RNAs reveals a detection panel of noncoding RNAs for liver cancer. Theranostics 2021;11:181-93. [PMID: 33391469 DOI: 10.7150/thno.48206] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Wu HY, Li QQ, Liang L, Qiu LL, Wei HW, Huang BY, Gang- C, He RQ, Huang ZG, Hou W, Hu QP, Pan SL. Prognostic alternative splicing signature in cervical squamous cell carcinoma. IET Syst Biol 2020;14:314-22. [PMID: 33399095 DOI: 10.1049/iet-syb.2019.0095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Wu HY, Peng ZG, He RQ, Luo B, Ma J, Hu XH, Dang YW, Chen G, Pan SL. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data. Int J Oncol 2019;55:425-38. [PMID: 31268164 DOI: 10.3892/ijo.2019.4834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
39 Li Y, McGrail DJ, Xu J, Mills GB, Sahni N, Yi S. Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation. Trends Biochem Sci 2018;43:576-92. [PMID: 29941230 DOI: 10.1016/j.tibs.2018.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Zhu GQ, Zhou YJ, Qiu LX, Wang B, Yang Y, Liao WT, Luo YH, Shi YH, Zhou J, Fan J, Dai Z. Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. Carcinogenesis 2019;40:1077-85. [PMID: 31099827 DOI: 10.1093/carcin/bgz073] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
41 Hong W, Zhang W, Guan R, Liang Y, Hu S, Ji Y, Liu M, Lu H, Yu M, Ma L. Genome-wide profiling of prognosis-related alternative splicing signatures in sarcoma. Ann Transl Med 2019;7:557. [PMID: 31807538 DOI: 10.21037/atm.2019.09.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Johnson NT, Dhroso A, Hughes KJ, Korkin D. Biological classification with RNA-seq data: Can alternatively spliced transcript expression enhance machine learning classifiers? RNA 2018;24:1119-32. [PMID: 29941426 DOI: 10.1261/rna.062802.117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
43 Xie ZC, Wu HY, Dang YW, Chen G. Role of alternative splicing signatures in the prognosis of glioblastoma. Cancer Med 2019;8:7623-36. [PMID: 31674730 DOI: 10.1002/cam4.2666] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
44 Jiang W, Chen L. Alternative splicing: Human disease and quantitative analysis from high-throughput sequencing. Comput Struct Biotechnol J 2021;19:183-95. [PMID: 33425250 DOI: 10.1016/j.csbj.2020.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Guo Y, Qi Y, Li Z, Shang X. Improvement of cancer subtype prediction by incorporating transcriptome expression data and heterogeneous biological networks. BMC Med Genomics 2018;11:119. [PMID: 30598111 DOI: 10.1186/s12920-018-0435-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer 2018;18:684. [PMID: 29940909 DOI: 10.1186/s12885-018-4591-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
47 Song X, Zeng Z, Wei H, Wang Z. Alternative splicing in cancers: From aberrant regulation to new therapeutics. Semin Cell Dev Biol 2018;75:13-22. [PMID: 28919308 DOI: 10.1016/j.semcdb.2017.09.018] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
48 Soto M, Reviejo M, Al-Abdulla R, Romero MR, Macias RIR, Boix L, Bruix J, Serrano MA, Marin JJG. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis 2020;1866:165687. [PMID: 31953214 DOI: 10.1016/j.bbadis.2020.165687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Isik Z, Ercan ME. Integration of RNA-Seq and RPPA data for survival time prediction in cancer patients. Comput Biol Med 2017;89:397-404. [PMID: 28869900 DOI: 10.1016/j.compbiomed.2017.08.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
50 Zhang D, Duan Y, Cun J, Yang Q. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma. Front Genet 2019;10:278. [PMID: 30984247 DOI: 10.3389/fgene.2019.00278] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
51 Luo CL, Xu XC, Liu CJ, He S, Chen JR, Feng YC, Liu SQ, Peng W, Zhou YQ, Liu YX, Wei PP, Li B, Mai HQ, Xia XJ, Bei JX. RBFOX2/GOLIM4 Splicing Axis Activates Vesicular Transport Pathway to Promote Nasopharyngeal Carcinogenesis. Adv Sci (Weinh) 2021;8:e2004852. [PMID: 34180133 DOI: 10.1002/advs.202004852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Qiu Y, Ching WK, Zou Q. Matrix factorization-based data fusion for the prediction of RNA-binding proteins and alternative splicing event associations during epithelial-mesenchymal transition. Brief Bioinform 2021;22:bbab332. [PMID: 34410342 DOI: 10.1093/bib/bbab332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Hershberger CE, Moyer DC, Adema V, Kerr CM, Walter W, Hutter S, Meggendorfer M, Baer C, Kern W, Nadarajah N, Twardziok S, Sekeres MA, Haferlach C, Haferlach T, Maciejewski JP, Padgett RA. Complex landscape of alternative splicing in myeloid neoplasms. Leukemia 2021;35:1108-20. [PMID: 32753690 DOI: 10.1038/s41375-020-1002-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
54 Park E, Pan Z, Zhang Z, Lin L, Xing Y. The Expanding Landscape of Alternative Splicing Variation in Human Populations. Am J Hum Genet 2018;102:11-26. [PMID: 29304370 DOI: 10.1016/j.ajhg.2017.11.002] [Cited by in Crossref: 152] [Cited by in F6Publishing: 128] [Article Influence: 38.0] [Reference Citation Analysis]
55 Tang Z, Chen T, Ren X, Zhang Z. Identification of transcriptional isoforms associated with survival in cancer patient. J Genet Genomics 2019;46:413-21. [PMID: 31630971 DOI: 10.1016/j.jgg.2019.08.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]